Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Xenetic Biosciences (NASDAQ:XBIO) has released a Virtual Investor segment featuring Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development. The segment focuses on the company's recent poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.
The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', highlights preclinical data in the company's immune-oncology program targeting difficult to treat cancers.
Xenetic Biosciences (NASDAQ:XBIO) ha pubblicato un segmento Virtual Investor con il Dr. Reid Bissonnette, Consulente Esecutivo per la Ricerca Traslazionale e lo Sviluppo. Il segmento si concentra sulla recente presentazione di poster dell'azienda alla riunione scientifica primaverile 2025 sulla Terapia Cellulare della Society for Immunotherapy of Cancer (SITC).
La presentazione, intitolata 'Intervento con DNase I Migliora la Terapia CAR-T nei Tumori Solidi Mirando alle Trappole Extracellulari dei Neutrofili nel Melanoma Metastatico', evidenzia dati preclinici nel programma di immuno-oncologia dell'azienda che mira a trattare tumori difficili da curare.
Xenetic Biosciences (NASDAQ:XBIO) ha lanzado un segmento de Inversor Virtual con el Dr. Reid Bissonnette, Consultor Ejecutivo para la Investigación y Desarrollo Traslacional. El segmento se centra en la reciente presentación de póster de la compañía en la Reunión Científica de Terapia Celular de Primavera 2025 de la Sociedad para la Inmunoterapia del Cáncer (SITC).
La presentación, titulada 'La Intervención con DNase I Mejora la Terapia CAR-T en Tumores Sólidos al Apuntar a las Trampas Extracelulares de Neutrófilos en el Melanoma Metastásico', destaca datos preclínicos en el programa de inmuno-oncología de la compañía que se dirige a cánceres difíciles de tratar.
제넥틱 바이오사이언스 (NASDAQ:XBIO)는 전이 연구 및 개발을 위한 수석 컨설턴트인 리드 비소네트 박사와 함께하는 가상 투자자 세그먼트를 발표했습니다. 이 세그먼트는 암 면역요법 학회(SITC) 2025년 봄 세포 치료 회의에서 회사의 최근 포스터 발표에 초점을 맞추고 있습니다.
‘DNase I 개입이 전이성 흑색종에서 호중구 세포외 덫을 표적으로 하여 CAR-T 세포 치료를 향상시킨다’라는 제목의 발표는 치료하기 어려운 암을 겨냥한 회사의 면역 종양학 프로그램에서의 전임상 데이터를 강조합니다.
Xenetic Biosciences (NASDAQ:XBIO) a publié un segment d'investisseur virtuel avec le Dr Reid Bissonnette, consultant exécutif en recherche et développement translationnel. Ce segment se concentre sur la récente présentation de poster de l'entreprise à la réunion scientifique de printemps 2025 sur la thérapie cellulaire de la Society for Immunotherapy of Cancer (SITC).
La présentation, intitulée 'L'intervention par DNase I améliore la thérapie CAR-T dans les tumeurs solides en ciblant les pièges extracellulaires des neutrophiles dans le mélanome métastatique', met en avant des données précliniques dans le programme d'immuno-oncologie de l'entreprise visant à traiter des cancers difficiles à soigner.
Xenetic Biosciences (NASDAQ:XBIO) hat ein virtuelles Investoren-Segment mit Dr. Reid Bissonnette, Executive Consultant für translationale Forschung und Entwicklung, veröffentlicht. Das Segment konzentriert sich auf die kürzliche Posterpräsentation des Unternehmens auf dem Frühjahrstagung 2025 zur Zelltherapie der Society for Immunotherapy of Cancer (SITC).
Die Präsentation mit dem Titel 'DNase I-Intervention verbessert die CAR-T-Zelltherapie bei soliden Tumoren, indem sie neutrophile extrazelluläre Fallen im metastasierenden Melanom angreift' hebt präklinische Daten im Immunonkologie-Programm des Unternehmens hervor, das sich auf schwer zu behandelnde Krebserkrankungen konzentriert.
- None.
- None.
- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
- Watch the "What This Means" video here
FRAMINGHAM, MA / ACCESS Newswire / April 9, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficult to treat cancers, today announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment.
As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent poster presentation titled, "DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma," which was presented at the at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.
The Virtual Investor "What This Means" segment featuring Xenetic is now available here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: ongoing pre-clinical studies with data expected before year end; focusing on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indications, the potential of our DNase-based oncology platform, focusing our resources on driving our pipeline towards first-in-human clinical studies and establishing proof-of-concept in multiple indications, our commitment to bringing a much-needed, innovative immune-oncology treatment to patients and generate shareholder value in the near and long term, and plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors, our focus on advancing innovative immune-oncology technologies addressing hard to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the Russian invasion of Ukraine and conflict in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What was presented at SITC 2025 Spring Scientific Cell Therapy Meeting by Xenetic Biosciences (XBIO)?
What is the focus of Xenetic Biosciences' (XBIO) research presented in April 2025?
Who presented Xenetic Biosciences' (XBIO) research at the SITC 2025 meeting?
What therapeutic area is Xenetic Biosciences (XBIO) targeting with their research?
